Trials / Completed
CompletedNCT00212355
Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.
Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Nobelpharma · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.
Detailed description
Wilson disease is an autosomal recessive disorder with copper metabolism. In Japan, the standard treatment is the use of copper chelating agents, such as D-penicillamine and trientine. In this study, we investigate efficacy on zinc acetate in Japanese patients with Wilson disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NPC-02 | zinc acetate |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2008-04-01
- Completion
- 2009-01-01
- First posted
- 2005-09-21
- Last updated
- 2025-03-05
- Results posted
- 2014-05-14
Source: ClinicalTrials.gov record NCT00212355. Inclusion in this directory is not an endorsement.